Navigation

Growth failure (in children) - human growth hormone (HGH) (review)

Human growth hormone for the treatment growth failure in children (review)

Status: History
Expected date of issue: TBC
Process: MTA
Topic area:
  • Endocrine, nutritional and metabolic
  • Therapeutic procedures
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Fay McCracken
Communications manager: Philip Ranson
Project manager: Jeremy Powell
Assessment Group / Evidence Review Group: Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: 4 April 2008
Information meeting with consultees: 13 June 2008
Closing date for invited submissions / evidence submission: 27 February 2009
Final scope published: August 2008
1st appraisal committee meeting: 03 November 2009
2nd appraisal committee meeting: 04 February 2010
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Eli Lilly & Co Ltd (somatropin)
  • Ferring Pharmaceuticals (UK) (somatropin)
  • Ipsen Ltd (somatropin)
  • MerckSerono (somatropin)
  • Novo Nordisk Ltd (somatropin)
  • Pfizer Ltd (somatropin)
  • Sandoz Limited (somatropin)

Patient/carer groups

  • Child Growth Foundation
  • Pituitary Foundation
  • Turner Syndrome Support Society

Professional groups

  • British Society For Paediatric Endocrinology and Diabetes
  • Royal College of Nursing
  • Royal College of Paediatrics & Child Health
  • Royal College of Pathologists
  • Royal College of Physicians
  • Society for Endocrinology

Others

  • Department of Health
  • Welsh Assembly Government

General

  • British National Formulary
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • NHS Quality Improvement Scotland

Comparator manufacturers

  • None

Relevant research groups

  • None

Assessment team

  • Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
  • National Coordinating Centre for Health Technology Assessment

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
9 June 2005 Topic created.
8 November 2006 On reviewing the consultation responses, in particular information from the manufacturers of the technologies for this appraisal, NICE has decided to postpone initiating the appraisal to update the existing guidance, to allow for pending new indications to receive regulatory approval.  We intend to set the timelines of the appraisal to coincide with the licensing process for these indications and will provide detailed appraisal timelines when we have more precise information.
30 November 2007 On reviewing responses in regards to the scope the Institute is currently liaising with the Department of Health on the possibility of splitting the scope in two.
11 March 2008 Confirmation regarding a split in the scope and the technology appraisal to resume. This technology appraisal to consult in draft scope and provide a post referral scoping workshop for consultees in June 2008.
Top


 

Key documents

This page was last updated: 25 April 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.